https://scholars.lib.ntu.edu.tw/handle/123456789/630330
標題: | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer | 作者: | Koppikar, S Oaknin, A Babu, K Govind Lorusso, D Gupta, S Wu, L-Y Rajabto, W Harano, K Hong, S-H Malik, R A Strebel, H Aggarwal, I M Lai, C-H Dejthevaporn, T Tangjitgamol, S WEN-FANG CHENG Chay, W Y Benavides, D Hashim, N M Moon, Y W Yunokawa, M Anggraeni, T D Wei, W Curigliano, G Maheshwari, A Mahantshetty, U Sheshadri, S Peters, S Yoshino, T Pentheroudakis, G |
關鍵字: | ESMO; Pan-Asian; endometrial cancer; guidelines; treatment | 公開日期: | 二月-2023 | 卷: | 8 | 期: | 1 | 來源出版物: | ESMO open | 摘要: | The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer was published in 2022. It was therefore decided, by both the ESMO and the Indian Society of Medical and Paediatric Oncology (ISMPO), to convene a virtual meeting in July 2022 to adapt the ESMO 2022 guidelines to take into account the variations in the management of endometrial cancer in Asia. These guidelines represent the consensus opinion of a panel of Asian experts representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). Voting was based on scientific evidence and was conducted independently of the current treatment practices and treatment access constraints in the different Asian countries, which were discussed when appropriate. The aim of this guideline manuscript is to provide guidance for the optimisation and harmonisation of the management of patients with endometrial cancer across the different regions of Asia, drawing on the evidence provided by Western and Asian trials whilst respecting the variations in clinical presentation, diagnostic practices including molecular profiling and disparities in access to therapeutic options, including drug approvals and reimbursement strategies. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630330 | ISSN: | 20597029 | DOI: | 10.1016/j.esmoop.2022.100774 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。